Abstract
8548 Background: Ublituximab (UTX) is a novel glycoengineered anti-CD20 mAb. TGR-1202 is a novel once daily oral PI3Kδ inhibitor. UTX + TGR-1202 has shown strong synergistic activity in-vitro (Luga...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have